PATENT CLAIM ANALYSIS

Application Number: 15757687
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2019-02
Patent Classification: ["424", "204100"]

Abstract:
The present invention relates to augmenting the effects of adoptive T cell therapy, such as TVAX Immunotherapy, using adjunct treatment with an oncolytic virus, such as a vaccinia virus, to treat various types of cancer or other proliferative disorders. Immunomodulatory compounds can be used to further augment to effects of the therapy.

Claim (Index 10):
The method of  claim 1 , further comprising before the vaccinating step, removing the patient's own malignancy and administering a first oncolytic virus to the patient, wherein administering the first oncolytic virus occurs simultaneously with or after the removing the patient's own malignancy.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 90.0
- Lexical Diversity: 1.34884
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15892247', '14792424', '14004546', '15129916', '13470558']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.732479701879545
- 35 USC 102 Novelty (BERT): 0.5081688149976723
- Combined Prediction Score: 0.7100486131913578
- Mean Citation Score: 263.860032
- Max Citation Score: 281.17853
- Similarity Product: 201.11722155727568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test